US Bancorp’s Rigel Pharmaceuticals RIGL Stock Holding History

US Bancorp’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,677	Closed	-$87.6K	–	4237
2025 Q2	$87.6K	Sell	4,677 -443	-9%	-$8.4K	﹤0.01%	2491
2025 Q1	$92.1K	Buy	5,120 +1,868	+57%	+$37.9K	﹤0.01%	2436
2024 Q4	$54.7K	Buy	3,252 +12	+0.4%	+$230	﹤0.01%	2696
2024 Q3	$52.4K	Hold	3,240	–	–	﹤0.01%	2715
2024 Q2	$26.6K	Sell	3,240 -200	-6%	-$2.09K	﹤0.01%	2948
2024 Q1	$50.9K	Sell	3,440 -1,269	-27%	-$17.1K	﹤0.01%	2680
2023 Q4	$68.3K	Buy	+4,709	New	+$48.2K	﹤0.01%	2509
2021 Q4	–	Sell	-99	Closed	-$4K	–	4204
2021 Q3	$4K	Hold	99	–	–	﹤0.01%	3727
2021 Q2	$4K	Hold	99	–	–	﹤0.01%	3675
2021 Q1	$3K	Hold	99	–	–	﹤0.01%	3635
2020 Q4	$3K	Buy	+99	New	+$2.87K	﹤0.01%	3517

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $23B AUM 48.97% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's RIGL Position: Q3 2025 in Review

US Bancorp sold out of Rigel Pharmaceuticals (RIGL) in Q3 2025, closing a stake of 4,677 shares — an estimated $87.6K sold.

US Bancorp first reported a position in RIGL in Q4 2020 and held it in 11 quarters. The position peaked at $92.1K in Q1 2025. 169 funds tracked by Wall St. Rank hold RIGL as of Q3 2025.

US Bancorp reported no remaining Rigel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
US Bancorp sold 4,677 Rigel Pharmaceuticals shares in Q3 2025, an estimated $87.6K.
US Bancorp first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 11 quarters.
US Bancorp's Rigel Pharmaceuticals position peaked at $92.1K in Q1 2025.
169 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2025.

Based on US Bancorp's 13F filing for Q3 2025, filed 12 Nov 2025.